← 返回

免疫指数:用于肝细胞癌免疫治疗反应预测的基因和细胞预后特征

英文原题:Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma.

查看英文原题

Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma.

PubMed 2022/11/26(内容时间) Pharmacol Res Q1 · IF 12.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤免疫微环境(TIME)的异质性在肝细胞癌(HCC)的发生发展和免疫治疗反应中发挥重要作用。我们利用机器学习算法,引入了免疫指数(IMI),这是一种基于HCC免疫景观的预后模型。我们发现,IMI低的HCC富集干细胞和增殖特征,与IMI高的HCC相比,伴有更多的TP53突变和17p缺失。更重要的是,IMI高的患者表现出更好的免疫检查点阻断(ICB)反应。为便于临床应用,我们采用机器学习算法开发了IMI的基因模型(IMI G),其包含10个基因。根据我们的HCC队列检测和单细胞水平分析,我们发现IMI G高的HCC表现出有利的生存结局以及高水平的NK和CD8 + T细胞浸润。最后,在与自体TIL(肿瘤浸润淋巴细胞)共培养后,IMI G高的肿瘤细胞对nivolumab治疗表现出更好的反应。总之,IMI和IMI G可作为HCC预后、分类和ICB治疗反应预测的有力工具。

展开英文摘要原文

The heterogeneity of tumor immune microenvironment (TIME) plays important roles in the development and immunotherapy response of hepatocellular carcinoma (HCC). Using machine learning algorithms, we introduced the immune index (IMI), a prognostic model based on the HCC immune landscape.

We found that IMI low HCCs were enriched in stem cell and proliferating signatures, and yielded more TP53 mutation and 17p loss compared with IMI high HCCs. More importantly, patients with high IMI exhibited better immune-checkpoint blockade (ICB) response.

To facilitate clinical application, we employed machine learning algorithms to develop a gene model of the IMI (IMI G ), which contained 10 genes. According to our HCC cohort examination and single-cell level analysis, we found that IMI G high HCCs exhibited favorable survival outcomes and high levels of NK and CD8 + T cells infiltration.

Finally, after coculture with autologous tumor infiltrating lymphocytes, IMI G high tumor cells exhibited a better response to nivolumab treatment. Collectively, the IMI and IMI G may serve as powerful tools for the prognosis, classification and ICB treatment response prediction of HCC.

论文信息

作者
Cui X、Han L、Cui L、Fu G、Liu E、Wang D、Song B、Zhang Y
第一作者单位
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.China
通讯作者单位
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China. Electronic address: fujing-724@163.com.China
文献类型
非美国政府资助研究
期刊
Pharmacological research2023 Jan
原文标识
PubMed 36574578 · DOI 10.1016/j.phrs.2022.106583